Drug General Information (ID: DDIU3CBFRL)
Drug Name			Droxidopa		Drug Info		Ozanimod		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Vasopressors				Selective Immunosuppressants
Structure

Mechanism of Droxidopa-Ozanimod Interaction (Severity Level: Moderate)
Additive hypertensive effects Click to Show/Hide Mechanism Graph
Drug Name		Droxidopa				Ozanimod
Mechanism		Hypertensive effects				Hypertensive effects
Key Mechanism Factor 1
		Factor Name		Hypertensive effects
		Factor Description		Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head.
Mechanism Description		Additive hypertensive effects by the combination of Droxidopa and Ozanimod

Recommended Action
Management		Concomitant use of droxidopa with nonselective MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) should be avoided. Selective MAO-B inhibitors such as rasagiline and selegiline were permitted in droxidopa clinical trials.

References
1	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
2	Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
3	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.